ALLMedicine™ Gastric Tumors Center
Research & Reviews 296 results
https://clinicaltrials.gov/ct2/show/NCT03008278
Aug 2nd, 2022 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...
https://clinicaltrials.gov/ct2/show/NCT03027427
Jul 20th, 2022 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...
https://doi.org/10.1007/s12328-022-01672-y
Clinical Journal of Gastroenterology; Rasmussen S, Stueck A et. al.
Jul 14th, 2022 - Gastrointestinal stromal tumors (GISTs) are usually caused by somatic mutations, but there are rare germline variants that predispose patients to the development of one or, more commonly, multiple GISTs. We present 2 cases of multifocal GISTs rela...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203228
Contrast Media & Molecular Imaging; Wang S, Hong Y et. al.
Jul 9th, 2022 - To explore the clinical value of the gastric ultrasonic filling method in evaluating the condition of patients with gastric tumors and guiding the selection of treatment methods, provide data support for clinical gastric filling ultrasonography in...
https://clinicaltrials.gov/ct2/show/NCT02491840
Jul 8th, 2022 - Some subtypes of gastric and cardia tumors such as adenocarcinoma or gastric linitis with disseminated cells respond poorly to the pre-operative chemotherapy, and some of them do not respond to chemotherapy usually performed. Doing chemotherapy in...
Drugs 5 results see all →
Clinicaltrials.gov 19 results
https://clinicaltrials.gov/ct2/show/NCT03008278
Aug 2nd, 2022 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...
https://clinicaltrials.gov/ct2/show/NCT03027427
Jul 20th, 2022 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...
https://clinicaltrials.gov/ct2/show/NCT02491840
Jul 8th, 2022 - Some subtypes of gastric and cardia tumors such as adenocarcinoma or gastric linitis with disseminated cells respond poorly to the pre-operative chemotherapy, and some of them do not respond to chemotherapy usually performed. Doing chemotherapy in...
https://clinicaltrials.gov/ct2/show/NCT05411432
Jun 9th, 2022 - 6 healthy volunteers with whole-body PET/CT scans at 0-1.0, 2.0, 3.0 and 4.0 hours after tracer injection (mean dose, 4.93 ± 0.10 mCi) will be performed. During the imaging period, 1 mL blood samples will be obtained specifically at 1, 3, 5, 10, 3...
https://clinicaltrials.gov/ct2/show/NCT05153746
Dec 10th, 2021 - An accumulating body of evidence has shown that detection and resection of pre-cancerous adenoma by colonoscopy could effectively prevent colorectal cancer (CRC) and its related mortality. Among various colonoscopy quality indicators, such as ceca...
News 24 results
https://www.medscape.com/viewarticle/964279
Dec 8th, 2021 - NEW YORK (Reuters Health) - How long patients with resected gastric adenocarcinoma survive is tied to their preoperative sensitivity to chemotherapy, researchers report. "Interestingly, in patients with sensitive tumors, there was a significant su...
https://www.onclive.com/view/trastuzumab-deruxtecan-shows-promise-beyond-breast-and-gastric-tumors
Oct 6th, 2021 - Bob T. Li, MD, MPH Fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201), a HER2-directed antibody¬—drug conjugate (ADC), demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types, according to findings ...
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/92785
May 25th, 2021 - Vonoprazan, a potassium-competitive acid blocker, was not superior to the proton pump inhibitor (PPI) lansoprazole (Prevacid) for healing artificial gastric ulcers among patients with gastric tumors, Japanese researchers found in a randomized, ope...
https://www.onclive.com/view/genetic-risk-screening-and-diagnosis-for-gastric-cancer
Apr 2nd, 2021 - Transcript:Johanna C. Bendell, MD: David, thinking about the family members, do you screen? Do you look at genetic risk factors for patients? David H. Ilson, MD, PhD: Just 1 other point about the global incidence is that there’s a shift globall...
https://www.onclive.com/view/emerging-nivolumab-strategies-in-gastric-gej-cancers
Apr 2nd, 2021 - Transcript: Yelena Y. Janjigian, MD: We know the majority of patients will not benefit from anti—PD-1 therapy alone. The gastric tumors, although they are immunogenic and immune visible, are not as visible as some of the other immunogenic tumo...